- Product Details
- Description
- Additional information
- More Offers
Description
Background Information:
CUDC-305 (DEBIO-0932) is an orally bioavailable inhibitor of Heat Shock Proteins, displaying high affinity for HSP90α/β (about 100 nM in IC50) and HSP90 complex derived from cancer cells (IC50= 48.8 nM). Exhibits high oral bioavailability (96.0%) and selective retention in tumor (half-life, 20.4 hours) compared with normal tissues. BBB Penetrant.
Reference:
1. R. Bao, et al, Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer, Mol Cancer Ther. 2009 Dec; 8(12), 3296-306.
2. R. Bao, et al, CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy, Clin Cancer Res. 2009 Jun 15; 15(12), 4046-57.
APIM050350: CUDC-305 (DEBIO-0932)
CAS No.: 1061318-81-7.
Molecular Formula: C22H30N6O2S.
Molecular Weight: 442.58.
Purity: >99.5% (HPLC at 214 and 254 nm).
QC: HPLC-MS, 1HNMR, and Quantitative Elemental Analysis.
Solubility: Soluble in DMSO, and water with 2 eq. of acid.
Storage: Store at 0°C (short term), -20°C (long term), desiccated.
Additional information
| Ship from Country | USA |
|---|---|
| Size | 10 mg, 100 mg, 200 mg, 5 mg, 50 mg |
